Coxsackievirus-induced myocarditis: New trends in treatment

Zhen Liu, Ji Yuan, Bobby Yanagawa, Dexin Qiu, Bruce M. McManus, Decheng Yang

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Myocarditis is a common inflammatory heart disease in children and young adults that may result in chronically dilated cardiomyopathy. Coxsacklevirus B3 is the major etiologic agent of this disease. Current treatments for patients with viral myocarditis are almost entirely supportive. In recent years, some promising therapeutic candidates have emerged, including novel treatments and improvements of existing drugs. Among these are molecules that specially target virus entry, such as pleconaril, WIN 54954 and CAR-Fc; nucleic acid-based antiviral agents that inhibit viral translation and/or transcription, such as antisense oligodeoxynucleotide and short interfering RNA; and immunomodulatory agents that augment the host-protective immune responses to effectively clear viruses from target tissues, including interferons and immunoglobulins. In addition, certain new antiviral strategies, still in the early stages, include modulation of signal transduction pathways responsible for viral replication using enzyme inhibitors, which have revealed potential therapeutic targets for viral myocarditis. Finally, the progress in cellular cardiomyoplasty for end-stage therapy, in particular the preliminary clinical trials, is also discussed with respect to its potential future application.

Original languageEnglish (US)
Pages (from-to)641-650
Number of pages10
JournalExpert Review of Anti-Infective Therapy
Volume3
Issue number4
DOIs
StatePublished - Aug 1 2005

Fingerprint

Enterovirus
Myocarditis
Antiviral Agents
Cardiomyoplasty
Therapeutics
Virus Internalization
Oligodeoxyribonucleotides
Dilated Cardiomyopathy
Enzyme Inhibitors
Nucleic Acids
Interferons
Small Interfering RNA
Immunoglobulins
Young Adult
Heart Diseases
Signal Transduction
Clinical Trials
Viruses
Pharmaceutical Preparations

Keywords

  • Antisense oligodeoxynucleotide
  • Cellular cardiomyoplasty
  • Coxsackievirus B3
  • Interferon
  • Pleconaril
  • Signal intervention
  • Small interfering RNA
  • Viral myocarditis
  • WIN compound

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases

Cite this

Coxsackievirus-induced myocarditis : New trends in treatment. / Liu, Zhen; Yuan, Ji; Yanagawa, Bobby; Qiu, Dexin; McManus, Bruce M.; Yang, Decheng.

In: Expert Review of Anti-Infective Therapy, Vol. 3, No. 4, 01.08.2005, p. 641-650.

Research output: Contribution to journalReview article

Liu, Zhen ; Yuan, Ji ; Yanagawa, Bobby ; Qiu, Dexin ; McManus, Bruce M. ; Yang, Decheng. / Coxsackievirus-induced myocarditis : New trends in treatment. In: Expert Review of Anti-Infective Therapy. 2005 ; Vol. 3, No. 4. pp. 641-650.
@article{7c015a7fbeb74852bac27252c9e8b59d,
title = "Coxsackievirus-induced myocarditis: New trends in treatment",
abstract = "Myocarditis is a common inflammatory heart disease in children and young adults that may result in chronically dilated cardiomyopathy. Coxsacklevirus B3 is the major etiologic agent of this disease. Current treatments for patients with viral myocarditis are almost entirely supportive. In recent years, some promising therapeutic candidates have emerged, including novel treatments and improvements of existing drugs. Among these are molecules that specially target virus entry, such as pleconaril, WIN 54954 and CAR-Fc; nucleic acid-based antiviral agents that inhibit viral translation and/or transcription, such as antisense oligodeoxynucleotide and short interfering RNA; and immunomodulatory agents that augment the host-protective immune responses to effectively clear viruses from target tissues, including interferons and immunoglobulins. In addition, certain new antiviral strategies, still in the early stages, include modulation of signal transduction pathways responsible for viral replication using enzyme inhibitors, which have revealed potential therapeutic targets for viral myocarditis. Finally, the progress in cellular cardiomyoplasty for end-stage therapy, in particular the preliminary clinical trials, is also discussed with respect to its potential future application.",
keywords = "Antisense oligodeoxynucleotide, Cellular cardiomyoplasty, Coxsackievirus B3, Interferon, Pleconaril, Signal intervention, Small interfering RNA, Viral myocarditis, WIN compound",
author = "Zhen Liu and Ji Yuan and Bobby Yanagawa and Dexin Qiu and McManus, {Bruce M.} and Decheng Yang",
year = "2005",
month = "8",
day = "1",
doi = "10.1586/14787210.3.4.641",
language = "English (US)",
volume = "3",
pages = "641--650",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Coxsackievirus-induced myocarditis

T2 - New trends in treatment

AU - Liu, Zhen

AU - Yuan, Ji

AU - Yanagawa, Bobby

AU - Qiu, Dexin

AU - McManus, Bruce M.

AU - Yang, Decheng

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Myocarditis is a common inflammatory heart disease in children and young adults that may result in chronically dilated cardiomyopathy. Coxsacklevirus B3 is the major etiologic agent of this disease. Current treatments for patients with viral myocarditis are almost entirely supportive. In recent years, some promising therapeutic candidates have emerged, including novel treatments and improvements of existing drugs. Among these are molecules that specially target virus entry, such as pleconaril, WIN 54954 and CAR-Fc; nucleic acid-based antiviral agents that inhibit viral translation and/or transcription, such as antisense oligodeoxynucleotide and short interfering RNA; and immunomodulatory agents that augment the host-protective immune responses to effectively clear viruses from target tissues, including interferons and immunoglobulins. In addition, certain new antiviral strategies, still in the early stages, include modulation of signal transduction pathways responsible for viral replication using enzyme inhibitors, which have revealed potential therapeutic targets for viral myocarditis. Finally, the progress in cellular cardiomyoplasty for end-stage therapy, in particular the preliminary clinical trials, is also discussed with respect to its potential future application.

AB - Myocarditis is a common inflammatory heart disease in children and young adults that may result in chronically dilated cardiomyopathy. Coxsacklevirus B3 is the major etiologic agent of this disease. Current treatments for patients with viral myocarditis are almost entirely supportive. In recent years, some promising therapeutic candidates have emerged, including novel treatments and improvements of existing drugs. Among these are molecules that specially target virus entry, such as pleconaril, WIN 54954 and CAR-Fc; nucleic acid-based antiviral agents that inhibit viral translation and/or transcription, such as antisense oligodeoxynucleotide and short interfering RNA; and immunomodulatory agents that augment the host-protective immune responses to effectively clear viruses from target tissues, including interferons and immunoglobulins. In addition, certain new antiviral strategies, still in the early stages, include modulation of signal transduction pathways responsible for viral replication using enzyme inhibitors, which have revealed potential therapeutic targets for viral myocarditis. Finally, the progress in cellular cardiomyoplasty for end-stage therapy, in particular the preliminary clinical trials, is also discussed with respect to its potential future application.

KW - Antisense oligodeoxynucleotide

KW - Cellular cardiomyoplasty

KW - Coxsackievirus B3

KW - Interferon

KW - Pleconaril

KW - Signal intervention

KW - Small interfering RNA

KW - Viral myocarditis

KW - WIN compound

UR - http://www.scopus.com/inward/record.url?scp=24044506253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044506253&partnerID=8YFLogxK

U2 - 10.1586/14787210.3.4.641

DO - 10.1586/14787210.3.4.641

M3 - Review article

C2 - 16107202

AN - SCOPUS:24044506253

VL - 3

SP - 641

EP - 650

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 4

ER -